Headline
The latest news stories.
The Senate passed the Health Care Cybersecurity and Resilience Act on Sept. 30 by unanimous consent.
Multiple changes to transparency in coverage requirements for insurers were finalized Oct. 5 by the Departments of the Treasury, Labor, and Health and Human Services.
An AHA blog published Oct. 5 responds to a Blue Cross Blue Shield Association report suggesting that hospitals’ use of artificial intelligence-enabled documentation tools is driving higher healthcare costs through increased coding intensity.
In this conversation, Nikki Daily, chief team resources officer at BayCare Health System, discusses how the organization is addressing Florida’s healthcare workforce shortage by building career pathways, developing apprenticeships and partnering with community organizations to create opportunities…
The AHA provided comments to the Medicare Payment Advisory Commission Oct. 2 on a discussion from the commission’s September meeting on its examination of differences in post-acute care use between beneficiaries enrolled in Medicare Advantage and fee-for-service Medicare.
The AHA, the New Hampshire Hospital Association and 340B Health have filed an amicus brief supporting Mary Hitchcock Memorial Hospital’s request for a preliminary injunction against Eli Lilly’s new 340B claims data policy.
A fifth measles-associated death was recorded in Pennsylvania, the state’s Department of Health announced Sept. 30.
The American Organization for Nursing Leadership will host a webinar Oct. 7 at noon ET that will explore how nurse leaders can shape enterprise artificial intelligence strategies to connect innovation, governance, workforce transformation and measurable care delivery outcomes.
The Centers for Medicare & Medicaid Services Sept. 30 finalized its Global Benchmark for Efficient Drug Pricing Model, also known as the GLOBE Model.
The Department of Health and Human Services announced a new clinical trials program through the Advanced Research Projects Agency for Health, or ARPA-H, that is designed to evaluate drugs and biologics faster, at lower cost and with fewer participants.